Présentation de l'entreprise
Allarity Therapeutics, Inc. operates as a clinical-stage precision medicine pharmaceutical company dedicated to developing novel anti-cancer therapeutics designed for patients with unmet medical needs. The firm specializes in creating drugs for the personalized treatment of cancer utilizing drug-specific companion diagnostics to enhance therapeutic efficacy. This entity functions within the healthcare sector, specifically the biotechnology industry, which distinguishes its operations from mature pharmaceutical giants by focusing on early-stage research and development rather than established product sales. The company's current financial scale is characterized by a market capitalization of $18.35 million, an annual revenue of $320,000, and a workforce consisting of 7 employees. These valuation and revenue metrics indicate that Allarity Therapeutics is a micro-cap entity in the early phases of commercialization or development, possessing a minimal operational footprint relative to its peer group in the biotechnology space.
Santé financière
The company reported revenue of $320,000 over the trailing twelve months, while posting a net income of $-11,231,000 and an EBITDA of $-12,596,000. The substantial disparity between the nominal revenue and the significant net loss reveals a cost structure dominated by research and development expenditures, administrative overheads, or clinical trial costs that far exceed current sales generation. Free cash flow stands at $-10,213,750, indicating that the company is burning through its liquidity reserves to fund operations and development activities, which limits immediate financial flexibility without external capital raises. Analysis of the three primary margins shows a gross margin of 100.0%, reflecting the nature of intellectual property assets or lack of cost of goods sold in the early stage; however, the operating margin of -911.9% and a profit margin of 0.0% highlight severe operational inefficiencies or high fixed costs relative to sales. The balance sheet holds $14.77 million in cash against $1.40 million in debt, resulting in a debt-to-equity ratio of 14.24, which suggests a leveraged position relative to equity though absolute debt levels remain low. A current ratio of 2.13 demonstrates that the company maintains sufficient current assets to cover short-term liabilities, providing a baseline of liquidity despite the cash burn. Return on Equity is recorded at -103.8% and Return on Assets at -38.5%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets held, a common trait for clinical-stage firms but one that signals a lack of immediate profitability.
Évaluation de la valorisation
Trailing twelve-month P/E Ratio is N/A due to the lack of earnings, while the forward P/E is listed as -1.20, a figure that implies earnings are not expected to turn positive in the near future based on current pricing models. The price-to-book ratio stands at 1.90, indicating that the market values the company at nearly twice its book value, which may reflect expectations of future asset appreciation or intangible value rather than current tangible assets. Alternative valuation metrics show a price-to-sales ratio of 57.34 and an EV/EBITDA of -0.40, suggesting that investors are pricing the stock based on potential future growth or pipeline value rather than current earnings power or cash flow generation. The 52-week high for the stock is $2.35 and the low is $0.61; without a specific current price provided in the data, the valuation range spans this $1.74 spread, highlighting significant intraperiod volatility. The beta value is 0.01, which indicates that the stock price exhibits virtually no volatility relative to the broader market, moving independently of general market trends and suggesting idiosyncratic risk rather than systematic risk.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings velocity against revenue expansion within the available dataset. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested or retained to fund ongoing operations and development initiatives. Since the company generates a net loss, the concept of a sustainable payout ratio is inapplicable, as there are no positive earnings to distribute to shareholders. The overall growth and income profile for Allarity Therapeutics is defined by a lack of historical growth data and the absence of income distribution, positioning the asset strictly as a venture-stage investment reliant on future clinical successes to unlock value.